[HTML][HTML] Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance
therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence …
therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence …
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Anti-cancer drugs, 2011 - journals.lww.com
Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
[HTML][HTML] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - Elsevier
Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease …
S Rajappa, DC Doval, J Biswas, S Patil… - South Asian Journal …, 2017 - thieme-connect.com
Bacground: First-line maintenance with erlotinib in nonsmall cell lung cancer (NSCLC)
patients without progression after four cycles of chemotherapy was well tolerated and …
patients without progression after four cycles of chemotherapy was well tolerated and …
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison
Background: Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …
[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
X Chen, Y Liu, OD Røe, Y Qian, R Guo, L Zhu, Y Yin… - PloS one, 2013 - journals.plos.org
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI),
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study
YL Wu, JH Kim, K Park, A Zaatar, G Klingelschmitt… - Lung cancer, 2012 - Elsevier
Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
相关搜索
- lung cancer maintenance erlotinib
- meta analysis maintenance erlotinib
- clinical outcomes maintenance erlotinib
- meta analysis clinical outcomes
- asian patients maintenance erlotinib
- disease progression maintenance erlotinib
- lung cancer asian patients
- lung cancer disease progression
- lung cancer survival benefit
- lung cancer indirect comparison
- erlotinib maintenance therapy
- pooled analysis efficacy of erlotinib
- unacceptable toxicity efficacy of erlotinib
- indirect comparison erlotinib and pemetrexed
- lung cancer maintenance therapy
- lung cancer maintenance treatment